[Analysis of risk factors for lymphoma patients dying of cardiovascular disease]

S Han1, W P Liu1, L Mi1

  • 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &Institute, Beijing 100142, China.

Insights

Cardiovascular disease is a significant cause of death in lymphoma patients, especially with longer survival times. Lymphoma stage and treatment-related cardiovascular toxicity increase this risk.

Area of Science:

  • Oncology
  • Cardiology
  • Epidemiology

Background:

  • Cardiovascular disease (CVD) poses a significant threat to lymphoma survivors.
  • Understanding CVD risk factors is crucial for improving long-term outcomes in lymphoma patients.

Purpose of the Study:

  • To identify independent risk factors for cardiovascular disease mortality in lymphoma patients.
  • To explore the relationship between lymphoma characteristics, treatment, and CVD death.

Main Methods:

  • Retrospective analysis of medical records and death information for 1,173 lymphoma patients.
  • Binary logistic regression model to determine independent risk factors for CVD death.
  • Stratification of mortality based on survival duration (5 and 10 years).

Main Results:

  • Cardiovascular disease accounted for 6.4% of deaths (75/1,173) in lymphoma patients.
  • Higher risk of CVD death was associated with advanced lymphoma stage (II-III) and cardiovascular toxicity during treatment.
  • Lymphoma primary site (non-lymph node) was linked to a lower risk of CVD mortality.

Conclusions:

  • Cardiovascular disease is a critical factor impacting lymphoma patient survival.
  • The risk of dying from CVD increases significantly with extended survival time.
  • Lymphoma stage and treatment-induced cardiovascular toxicity are key independent risk factors for CVD mortality.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
562
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
242
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
723
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
654
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
647
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.4K